Studying the influence of formulation and process variables on Vancomycin-loaded polymeric nanoparticles as potential carrier for enhanced ophthalmic delivery.

Seham Elkheshen , CarolYousry, Hanan M.El-laithy, TamerEssam, Rania H.Fahmy

Abstract

Ocular topically applied Vancomycin (VCM) suffers poor bioavailability due to its high molecular weight and hydrophilicity. In the present investigation, VCM-loaded polymeric nanoparticles (PNPs) were developed aiming to enhance its ocular bioavailability through prolonging its release pattern and ophthalmic residence. PNPs were prepared utilizing double emulsion (W/O/O), solvent evaporation vgejpkswg0"45" "63"hwnn"hcevqtkcn" fgukip" y cu"cr rnkg f"vq"gxcnwcvg"kp fkxk fwcn"cp f" eq o dkpgf"kphnwgpegu"qh"rqn{ o gt"v{ rg."Gwftcikv Ì "TU322."uqpkecvkqp"vk o g."cpf" Urcp **Ì** : 2"eqpegpvtcvkqp"qp"RPRu"rctvkeng"uk | g. "gpecruwncvkqp"ghhkekgpe{."cpf" | gvc" rqvgpvkcn0"Hwtvjgt."vjg"qrvkok|gf"hqtowncg"ygtg"kpeqtrqtcvgf"kp"3 ' "Ectdqrqn I/ based gel. In-vivo evaluation of the optimized formulae was performed via Draize test followed by microbiological susceptibility testing on albino rabbits. Results revealed successful formulation of VCM-loaded PNPs was achieved with particle sizes reaching 155 nm and up to 88% encapsulation. Draize test confirmed the optimized formulae as non-irritating and safe for ophthalmic administration. Microbiological susceptibility testing confirmed prolonged residence, higher Cmax. with more than two folds increment in the AUC(0.25646+" of VCM-PNPs over control groups. Thus, VCM-loaded PNPs represent promising carriers with superior achievements for enhanced Vancomycin ophthalmic delivery over the traditional use of commercially available VCM parenteral powder after constitution into a solution by the ophthalmologists.

European Journal of Pharmaceutical Sciences 2017, March